Novacap SAS

06/28/2018 | Press release | Distributed by Public on 06/28/2018 02:19

Novacap completes the acquisition of PCI Synthesis and expands its pharmaceutical offering in the U.S.

Based in Newburyport, MA PCI Sunthesis is the largest small molecule drug substance manufacturer in the New England area. PCI Synthesis is also a commercial manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products for the medical device industry. As a CDMO, PCI Synthesis provides emerging and mid-sized pharmaceutical companies access to the expertise needed to develop and manufacture complex small molecules.

Read the press release

more about PCI Synthesis